Immuno-oncology (I/O) being such a highly diverse therapeutic area requiring specialist knowledge to progress in the field. The development of new immunotherapies still faces many challenges. Crown Bioscience have gained unrivalled preclinical and translational I/O experience through our partnerships with the world's leading I/O companies.
Leverage our I/O in vitro and ex vivo services to quickly identify the right target for your immunotherapy. We offer a wide range of assays and platforms for in vitro testing of I/O agents, including core immunophenotyping, functional assays, and technologies for the regulation of the tumor microenvironment, allowing you to move with confidence to the next phase of drug development.
We understand that the complexity of I/O requires niche preclinical models for the most effective and translatable results. With that, we’ve developed a variety of validated in vivo models, specifically designed to answer a wide range of research questions.
We have expertise in applying these models and assays with range of immunotherapeutic's such as checkpoint inhibitors, vaccines, oncolytic viruses, microbiome modulators, cellular therapies (CAR-T), bi-specific T Cell engagers and various immune modulators.